77068-02-1

Basic information

• Product Name: N-(4-chloro-2-methylphenyl)-5-fluoro-2-hydroxybenzamide
• Synonyms: N-(4-Chloro-2-methylphenyl)-5-fluoro-2-hydroxybenzamide
• CAS NO: 77068-02-1
• Molecular Formula: C₁₄H₁₁ClFNO₂
• Molecular Weight: 279.694
• Mol File: 77068-02-1.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 352.479°C at 760 mmHg
• Flash Point: 166.974°C
• Density: 1.404g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.647
• CAS DataBase Reference: N-(4-chloro-2-methylphenyl)-5-fluoro-2-hydroxybenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-chloro-2-methylphenyl)-5-fluoro-2-hydroxybenzamide(77068-02-1)
• EPA Substance Registry System: N-(4-chloro-2-methylphenyl)-5-fluoro-2-hydroxybenzamide(77068-02-1)

Safety Data

• Hazardous Substances Data: 77068-02-1(Hazardous Substances Data)

Upstream product

• 345-16-4 5-fluoro-2-hydroxybenzoic acid 
• 95-69-2 4-chloro-2-methylbenzeneamine 

Downstream Products

• 77068-03-2 Acetic acid 2-(4-chloro-2-methyl-phenylcarbamoyl)-4-fluoro-phenyl ester 

Relevant articles and documents

INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA

Compounds and methods are provided for inhibiting a CREB-CBP protein-protein interaction in a sample. In some cases, the method includes modulating transcription of CREB in a cell that overexpresses CREB. Also provided are methods of inhibiting the proliferation of a cancer cell. The subject CREB transcription inhibitor compounds include a substituted salicylamide or a prodrug thereof. Methods of alleviating symptoms associated with cancer (e.g., Acute Myeloid Leukemia (AML) or Acute Lymphomblastic Leukemia (ALL)) in a subject in need thereof are also provided. Pharmaceutical compositions including the subject compounds find use in treating cancer. The subject compounds may be formulated or provided to a subject in combination with a second agent, e.g. an anticancer agent.